CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.

ABSTRACT:

Background

Neurofilament light chain is a marker of axonal damage and is of interest as a biofluid biomarker for PD. The objective of this study was to investigate whether CSF or serum neurofilament contributes to a combination of CSF biomarkers in defining the optimal biomarker panel for discriminating PD patients from healthy controls. In addition, we aimed to assess whether CSF and/or serum neurofilament levels are associated with clinical measures of disease severity.

Methods

We measured neurofilament light chain levels in CSF and/or serum of 139 PD patients and 52 age-matched healthy controls. We used stepwise logistic regression analyses to test whether neurofilament contributes to a biomarker CSF panel including total, oligomeric, and phosphorylated α-synuclein and Al

SUBMITTER: Oosterveld LP 

PROVIDER: S-EPMC7027879 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature